Farmos-yhtyma Oy

Orion Corporation

Orion-yhtyma Oy

Raimo E Virtanen

Arto J Karjalainen

Risto A Lammintausta

Arja L Karjalainen

Antti Haapalinna

Jyrki Lehtim&auml;ki

Kauko O Kurkela

Arja Karjalainen

Paavo Huhtala

Ewen MacDonald

Arto Olavi Urtti

Jari Ratilainen

Jarmo Sakari Salonen

Martti Marvola

Kauko Kurkela

Ilkka Larma

Maire M Eloranta

Timo Viitamaa

Outi M Vainio-Kivinen

Antti T Vaha-Vahe

Tiina Leino

Sakari A Nieminen

Mauno M Airaksinen

Antti Valjakka

Riitta A Miettinen

Marianne Karlsson

Jouni S Sirvio

Paavo Riekkinen, Jr

Paavo J Riekkinen

Thomas Yorio

Ilkka Linnankoski

Antti Pertovaara

Antti S Haapalinna

Hannu T Sipila

Eino J Savolainen

The present invention relates to a method for obtaining analgesia by administering 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enetiomer or pharmaceutically acceptable ester or salt thereof to a mammal intraspinally, 3-(1H-imidazol-4-ylmethyl)-indan-5-ol, its enantiomer or a pharmaceutically acceptable ester or salt thereof can be administered intraspinally to a mammal obtaining analgesia without side-effects, such as sedation. The present invention also relates to a method for using the drug as an adjunct to anaesthesia by administering it intraspinally.

Use of 3-(1H-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration

A method of administering transmucosally, particularly to oral or nasal mucosa, levosimendan or a pharmaceutically acceptable salt thereof to a patient. The method comprises contacting an intact mucous membrane with a source of levosimendan, and maintaining said source with said mucous membrane for a sufficient time period to deliver levosimendan to the patient. Transmucosal preparations of levosimendan are also described. Levosimendan is useful in the treatment of heart failure.

Transmucosal formulations of levosimendan

Imidazole derivatives

Polycyclic indanylimidazoles with alpha2 adrenergic activity

The present invention is in the art of eliciting a yohimbine-like alpha-adrenoreceptor antagonistic noradrenergic neurotransmission male sexual activity response in penile erection. The improvement involves a more rapid onset of action and improved effect than that of yohimbine, consisting essentially of the step of administering the compound atipamezole or a pharmaceutically acceptable acid addition salt thereof to a male in need thereof. Atipamezole or pharmaceutically acceptable acid salt thereof may be administered perorally, intravenously, intramuscularly, transmucosally or transdermally.

Administration of atipamezole to elicit a yohimbine-like

4(5) substituted imidazoles and their preparation and use

Imidazoles for the treatment of age-related cognitive disorders and

Compounds of formula: ##STR1## where X is --CH.sub.2 --, --CH(CH.sub.3)--, --CHR.sub.3 --CH.sub.2 -- or --CR.sub.3 .dbd.CH-- and R.sub.1, R.sub.2 and R.sub.3, which can be the same or different, are each H or CH.sub.3 or a stereoisomer or pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing them, are useful for lowering intraocular pressure in a mammal, e.g. in the treatment of glaucoma.

Compositions and their use in lowering intraocular pressure

Compounds of the formula: ##STR1## wherein X is --CH.sub.2 -- or ##STR2## R.sub.1 is H, C.sub.1-5 -alkyl or benzyl, which can be substituted or unsubstituted

Substituted imidazole derivatives and their preparation and use

The separated d and l enantiomers of medetomidine and their salts are selective and potent .alpha..sub.2 -receptor agonists.

Optical isomer of an imidazole derivative medetomidine as an

Medetomidine is useful in the treatment of anxiety disorders.

Anxiolytic composition

A process for the preparation of a substituted imidazole of the formula ##STR1## wherein X is --CH.sub.2 --, --CH.sub.2 CH.sub.2 -- or --O-- R.sub.1 is H, lower alkyl or lower alkenyl, OCH.sub.3 or OCH.sub.2 CH.sub.3, R.sub.2 is H, CH.sub.3, CH.sub.2 CH.sub.3, OCH.sub.3 or OH, R.sub.3 is H, CH.sub.3, CH.sub.2 CH.sub.3, OCH.sub.3 or Hal, R.sub.4 is H, CH.sub.3, CH.sub.2 CH.sub.3, OCH.sub.3 or Hal, and Hal is halogen and their non-toxic acid addition salts exhibit valuable pharmacological activity and are useful especially as selective .alpha..sub.2 -receptor antagonists.

4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and

4-[(.alpha.-Methyl)-2,3-dimethyl-benzyl]imidazole is useful as a veterinary sedative-analgetic agent, especially in small mammals.

Method of bringing about sedation and/or analgesia in a mammal

Growing community of inventors

Rusko, Finland

Raimo E Virtanen